Skip to content

Immunome

US · IMNM #2671 by market cap Listed 2020
15.69 -0.92 -5.54%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
  • Total institutional ownership fell 4.8 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
106.34% -4.81pp
Institutions
252 +1
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund83.43%
Hedge Fund10.76%
VC/PE Fund4.33%
Public Company3.63%
Private Company3.59%
Individual/Insider1.11%
Government Pension Fund0.29%
Insurance Company0.20%

Top holders as of 2026-06-30

T. Rowe Price Group, Inc. 18.17% · 21.45M sh
FMR 14.43% · 17.04M sh
BlackRock 7.56% · 8.93M sh
Wellington Management Group 4.41% · 5.21M sh
Redmile Group, LLC 4.16% · 4.91M sh
Vanguard Capital Management, LLC 4.13% · 4.88M sh
Sirenia Capital Management LP 4.09% · 4.83M sh
PRIMECAP Management Company 3.88% · 4.58M sh
State Street Global Advisors 3.81% · 4.49M sh
Driehaus Capital Management LLC 3.68% · 4.35M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 31 buys · 19 sells

NameRoleStake
Clay Siegall Chairperson & CEO 0.58%
Philip Wagenheim Independent Director 0.29%
Isaac Barchas Lead Independent Director 0.08%
Max Rosett Chief Financial Officer 0.05%
Jean-Jacques Bienaime Independent Director 0.04%
Philip Tsai Chief Technology Officer 0.04%
Jack Higgins Chief Scientific Officer 0.02%
Robert Lechleider Chief Medical Officer 0.01%
Sandra Stoneman Chief Legal Officer 0.00%
James Boylan Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-10 Jack Higgins Chief Scientific Officer Other Disposition -4,000 --
2026-09-10 Jack Higgins Chief Scientific Officer Derivative Exercise and Sale -18,000 $1.35–25.32
2026-08-11 Isaac Barchas Lead Independent Director Automatic Disposition -11,048 $27.25
2026-08-03 Kinney Horn Former Chief Business Officer Derivative Exercise and Sale -90,616 $10.60–25.09
2026-07-22 Clay Siegall Chairperson & CEO Other Acquisition +180,000 --
2026-07-22 Clay Siegall Chairperson & CEO Other Derivative Acquisition +360,000 $22.01
2026-07-22 Jack Higgins Chief Scientific Officer Other Acquisition +38,250 --
2026-07-22 Jack Higgins Chief Scientific Officer Other Derivative Acquisition +76,500 $22.01
2026-07-22 Robert Lechleider Chief Medical Officer Other Acquisition +54,000 --
2026-07-22 Robert Lechleider Chief Medical Officer Other Derivative Acquisition +108,000 $22.01
2026-07-22 Sandra Stoneman Chief Legal Officer Other Acquisition +38,250 --
2026-07-22 Sandra Stoneman Chief Legal Officer Other Derivative Acquisition +76,500 $22.01
2026-07-22 Kinney Horn Former Chief Business Officer Other Acquisition +31,250 --
2026-07-22 Kinney Horn Former Chief Business Officer Other Derivative Acquisition +62,500 $22.01
2026-07-22 Max Rosett Chief Financial Officer Other Acquisition +47,250 --
2026-07-22 Max Rosett Chief Financial Officer Other Derivative Acquisition +94,500 $22.01
2026-07-22 Philip Tsai Chief Technology Officer Other Acquisition +38,250 --
2026-07-22 Philip Tsai Chief Technology Officer Other Derivative Acquisition +76,500 $22.01
2026-07-06 Kinney Horn Former Chief Business Officer Derivative Exercise and Sale -1,092 $12.92–25.00
2026-07-01 Robert Lechleider Chief Medical Officer Derivative Exercise and Sale -55,000 $8.73–23.44

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Immunome discussion 0 comments

Add a comment